Get the Stockscreener App
131.80
1.43%
2.1251
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $131.80, with a volume of 1.44M.
It is up +1.43% in the last 24 hours and down -4.45% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$129.67
Open:
$129.5
24h Volume:
1.44M
Relative Volume:
0.24
Market Cap:
$163.67B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
17.93
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
-2.53%
1M Performance:
-4.45%
6M Performance:
+2.69%
1Y Performance:
+23.89%
1-Day Range:
$128.34
$132.34
1-Week Range:
$128.34
$135.07
52-Week Range:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.82 | 160.99B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,012.69 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.22 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.81 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
186.16 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
150.83 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Profund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health - ChartMill
Gilead Sciences Q1 2026 Earnings: Revenue Beat, Raised Guidance, and Key Analyst QuestionsNews and Statistics - IndexBox
Handelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
HighTower Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
Insider Sell Alert: Andrew Dickinson Sells Shares of Gilead Scie - GuruFocus
Gilead Sciences (NASDAQ:GILD) Insider Sells $3,676,120.00 in Stock - MarketBeat
Gilead Sciences Insider Sold Shares Worth $3,676,199, According to a Recent SEC Filing - Moomoo
Gilead Sciences CFO Andrew Dickinson sells $396,810 in stock - Investing.com India
Gilead (GILD) CFO Andrew Dickinson sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead (GILD) executive sells 28,000 shares, exercises 25,000 options - Stock Titan
Gilead Sciences (NASDAQ: GILD) sells $3.0B of senior notes due 2028–2034 - Stock Titan
Cipla Flips Gilead’s ‘End Run’ Claim in Descovy Patent Fight - Bloomberg Law News
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
WealthPlan Investment Management LLC Acquires 10,256 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
TD Private Client Wealth LLC Acquires 17,944 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
45,461 Shares in Gilead Sciences, Inc. $GILD Purchased by North Dakota State Investment Board - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating a 21.90% Upside Potential for Investors - DirectorsTalk Interviews
Erste Group Bank Predicts Gilead Sciences FY2026 Earnings - MarketBeat
Gilead Sciences Inc stock (US3755581036): dividend growth and HIV/oncology pipeline in focus - AD HOC NEWS
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline - MarketBeat
Leuthold Group LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
L & S Advisors Inc Invests $5.09 Million in Gilead Sciences, Inc. $GILD - MarketBeat
iA Global Asset Management Inc. Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
STF Management LP Sells 11,745 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
DNB Asset Management AS Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Canada Post Corp Registered Pension Plan - MarketBeat
Abacus Wealth Partners LLC Buys Shares of 12,486 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Evaluating Gilead Sciences (GILD) Valuation After Q1 Beat Guidance Shift And New HIV Priority Review - Yahoo Finance
Gilead Sciences Inc stock (US3755581036): Insider share sale plans draw attention to valuation and p - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Andrew Dickinson to sell 3,000 GILD shares, Form 144 (NASDAQ: GILD) - Stock Titan
Officer files Form 144 — GILD (NASDAQ: GILD) lists 25,000-share option sale - Stock Titan
Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences prices $3B multi-tranche senior notes offering - MSN
Gilead Sciences Prices $3 Billion Debt Offering - Moomoo
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc. - MarketBeat
Atria Investments Inc Acquires 12,906 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Prices $3B Senior Unsecured Notes Offerin - GuruFocus
Arbejdsmarkedets Tillaegspension Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is AustralianSuper Pty Ltd's 9th Largest Position - MarketBeat
Ameritas Advisory Services LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead Prices $3 Billion of Senior Unsecured Notes - New Castle News
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
153,779 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Sale |
131.29 |
28,000 |
3,676,199 |
125,779 |
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):